9月28日晚间，南京医药（600713）披露关于签订《战略投资协议》的公告。 公司与广州白云山医药集团股份有限公司（以下简称"白云山"）及广州广药股权投资合伙企业（有限合 伙）（以下简称"广药二期基金"）签署《战略投资协议》。 目前，南京医药股票价格为4.88元/股，与现价相比，转让价格略有溢价。 白云山位于广州，公司是A+H上市公司，目前市值约413亿元。 公司主要从事：（1）中西成药、化学原料药、天然药物、生物医药、化学原料药中 间体的研究开发、 制造与销售；（2）西药、中药和医疗器械的批发、零售和进出口业务；（3） 大健康产品的研发、生 产与销售；及（4）医疗服务、健康管理、养生养老等健康产业投资等。 白云山是南派中药的集大成者，大南药板块主要为医药制造业务，下属共有 27 家医药制造企业与机 构，从事中西成药、化学原料药、化学原料 药中间体、生物医药和天然药物等的研发、制造与销售。 大健康板块主要为饮料、食品、保健品等产品的生产、研发与销售，主要从事的企业包括本公司下属子 公司王老吉大健康公司及王老吉药业等。 大商业板块主要为医药流通业务，包括医药产品、医疗器械、保健品等的批发、零售与进出口业务，主 ...

证券日报网讯深桑达A9月26日在互动平台回答投资者提问时表示，公司秉持包容开放的心态与各类行 业参与者开展业务合作。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CCIAM Future Energy Limited 信能低碳有限公司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （股份代號：145） 自願公佈 協議備忘錄 本公佈乃由信能低碳有限公司（「本公司」）自願作出，以向本公司股東及潛在投 資者提供與本公司及其附屬公司（「本集團」）最新業務發展有關的資料。 協議備忘錄 本公司的全資附屬公司信能工程為一間根據香港法律正式註冊成立的公司。其主 要從事節能業務。 有關KEY ACTION的資料 Key Action為一間根據英屬處女群島法律正式註冊成立的公司，主要從事投資控股。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月四日，本公司 的全資附屬公司信能工程（中國）有限公司（「信能工程」）與Key Action Limited （「Key Action」）訂立協議備忘錄（「協議備忘錄」）。 根據協議備忘錄，信能工程同意與Key Act ...

Group 1 - The company reported a profit of approximately RMB 306.5 million for the first half of 2025, reversing a loss of RMB 247.3 million from the same period in 2024, primarily due to increased other income and reduced sales, distribution, R&D, and administrative expenses, partially offset by decreased revenue [1] - Adjusted loss decreased by RMB 178.9 million or 82.7% to RMB 37.4 million for the first half of 2025, compared to an adjusted loss of RMB 216.2 million for the first half of 2024 [1] - The adjusted loss was derived from the reported profit of RMB 59.2 million, excluding the impact of share-based payment expenses, write-offs of right-of-use assets, and lease termination gains/losses [1] Group 2 - The company began a strategic partnership with Baiyang Pharmaceutical in August 2025, appointing its subsidiaries as exclusive contract sales organizations for marketing services and distribution in mainland China, Hong Kong, and Macau, with a strategic cooperation fee of RMB 50 million [2] - Baiyang Pharmaceutical's subsidiary subscribed for 74,971,468 shares of the company, representing 14.99% of the enlarged issued share capital, for a total consideration of approximately HKD 100 million [2] - Despite challenges in the first half of 2025, the company remains optimistic for the second half, focusing on streamlining its product line and enhancing capital efficiency, expecting improved performance through deeper collaboration with Baiyang Pharmaceutical [2]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Bentley Huajun (Hainan) Food Co., Ltd. to explore potential business collaboration in product sales and marketing in mainland China and Hong Kong [1] Group 1: Strategic Cooperation Agreement - The agreement includes the establishment of a subsidiary, China Bentley Investment Co., Ltd., to jointly develop the Chinese sauce-flavored liquor market with Bentley Huajun [1] - Bentley Huajun will primarily focus on investments in wine, healthcare, artificial intelligence, high-tech agriculture, and supply chain, while the company will handle brand promotion and marketing for the liquor business [1] - Specific details and terms of the business development are subject to further negotiation between the two parties [1] Group 2: Business Expansion and Opportunities - The group is actively seeking joint ventures, business collaborations, and investment opportunities in the Greater Bay Area [1] - The board believes that the strategic cooperation presents a valuable opportunity to expand the company's revenue sources by broadening its business scope [1] - By leveraging Bentley Huajun's expertise in business and sales with the company's marketing services, the partnership is expected to create synergies for promoting and developing the business in the Chinese market [1]

Core Viewpoint - The renewal of the agreement between Baibang Technology and Apple is aligned with the company's strategic development direction and is expected to enhance business scope and operational performance [1] Group 1 - Baibang Technology's wholly-owned subsidiary, Shanghai Baibang, has renewed the "Apple Authorized Service Provider Agreement" with Apple Computer Trading (Shanghai) Co., Ltd. [1] - The contract has been extended until June 30, 2029 [1] - This renewal is beneficial for expanding the company's business range and improving operational performance [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with its major shareholders to enhance operational efficiency and pursue high-quality development through resource sharing and collaboration [2][3]. Group 1 - The agreement involves the termination of a previous cooperation agreement signed on May 27, 2016, and the acquisition of 100,000,000 shares (28.06% of total shares) held by the original controlling shareholder, Dalian Friendship Group [2]. - The parties have agreed to leverage their respective advantages to support Dalian Friendship in improving its operational performance and achieving high-quality growth [2][3]. Group 2 - The cooperation will include diversified and in-depth collaboration in equity and business areas, such as increasing shareholding in Dalian Friendship and engaging in retail and new retail business partnerships [3]. - Both parties aim to utilize their resources and industrial strengths to enhance cooperation, empower each other, and achieve win-win development [3].

Group 1 - The core viewpoint of the article highlights the meeting between Funiu Co., Ltd. and China Resources Power in Nanjing, focusing on enhancing business cooperation and communication [1] - Both parties agreed to deepen communication and trust in areas such as power asset management and shareholder rights protection [1] - The discussion emphasized leveraging each other's resource advantages to achieve win-win development [1]

Core Viewpoint - The company is actively collaborating with Hangzhou Yushu Technology Co., Ltd., with ongoing efforts to enhance the scale of their business partnership [1] Group 1 - The company primarily engages in the trading and trading services of electronic components [1] - The collaboration with Yushu Technology is still in the advancement stage, indicating potential for future growth [1] - The company has not sold Yushu's robotic products directly, but merchants within its "Huaqiang Electronic World" do offer these products [1]

Core Insights - Starbucks reported revenue growth and same-store sales increase in its China segment for Q3 of fiscal year 2025, with profit margins continuing to rise quarter-over-quarter [1] - The CEO highlighted that recent adjustments in China are yielding positive results, with three consecutive quarters of revenue and same-store sales growth [1] - Innovations in sugar-free beverages and new customization options have increased customer purchase frequency, while price adjustments in non-coffee products have broadened the customer base and enhanced consumption during lunch and evening periods [1] Strategic Developments - The company is exploring the sale of a portion of its equity in China, seeking strategic partners that share similar visions and values to capitalize on the significant growth potential in the Chinese market [1] - Starbucks is evaluating over 20 institutions that have shown strong interest in partnership, reaffirming its confidence and commitment to the Chinese market while aiming to retain a substantial equity stake in its operations [1] - The strong interest from potential partners reflects the company's robust team, strong brand presence, and long-term growth opportunities in China, with any transaction needing to align with Starbucks' interests [1]